MEN-1703 is under clinical development by Stemline Therapeutics and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Relapsed Acute Myeloid Leukemia have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MEN-1703’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MEN-1703 overview
MEN-1703 is under development for the treatment of acute myeloid leukemia (newly diagnosed), relapsed and refractory acute myeloid leukemia (AML), relapsed/refractory diffuse large B-cell lymphoma, myelofibrosis and multiple myeloma (kahler's disease), mantle cell lymphoma and marginal zone lymphoma cells and Hodgkin lymphoma. The drug candidate is administered through oral route and formulated as capsule. It acts by targeting both PIM kinase and FLT3. It was also under development for chronic myelocytic leukemia, solid tumors, chronic lymphocytic leukemia.
Stemline Therapeutics overview
Stemline Therapeutics (Stemline), a subsidiary of A. Menarini Industrie Farmaceutiche Riunite Srl, is a clinical stage biopharmaceutical company that develops therapeutics to treat cancer stem cells. The company pipeline products include TAGRAXOFUSP, ELACESTRANT, SL-701, MEN1611, MEN1611, MEN1309, FELEZONEXOR and SL-901. Stemline products treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), breast cancer, acute myeloid leukemia (AML), colorectal cancer (CRC) and solid tumors. It also carries out the development and commercialization of novel oncology therapeutics. The company has operations across Europe. Stemline is headquartered in New York, the US.
For a complete picture of MEN-1703’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
